PF 4064900
Alternative Names: PF-4064900Latest Information Update: 12 Aug 2009
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antibacterials
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Bacterial infections in USA (unspecified route)
- 30 Sep 2008 Phase-I clinical trials in Bacterial infections in USA (unspecified route)